Vaccitech plc (VACC)

$ 12.08
+0.46 (+3.96%)
-
Symbol VACC
Price $ 12.08
Beta 0.000
Volume Avg. 0.02M
Market Cap 0.421B
Shares () -
52 Week Range 11.21-17.99
1y Target Est -
DCF Unlevered VACC DCF ->
DCF Levered VACC LDCF ->
ROE -78.67% Strong Sell
ROA -14.86% Sell
Operating Margin -
Debt / Equity 3.98% Neutral
P/E -
P/B 1.21 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest VACC news


Mr. William J. Enright
Healthcare
Biotechnology
Nasdaq Global Select

Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.